These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34254647)

  • 1. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
    Zhu Y; Wang C; Li M; Yang X
    J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
    Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
    Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
    Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
    Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
    Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
    Altman JK; Szilard A; Konicek BW; Iversen PW; Kroczynska B; Glaser H; Sassano A; Vakana E; Graff JR; Platanias LC
    Blood; 2013 May; 121(18):3675-81. PubMed ID: 23509154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting MNK Selectively Targets Cervical Cancer via Suppressing eIF4E-Mediated β-Catenin Activation.
    Zhang W; Su X; Li S; Wang Y; Wang Q; Zeng H
    Am J Med Sci; 2019 Sep; 358(3):227-234. PubMed ID: 31327462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MNK/eIF4E inhibition overcomes anlotinib resistance in non-small cell lung cancer.
    Zhang Q; Li H; Li Q; Hu Q; Liu B
    Fundam Clin Pharmacol; 2023 Apr; 37(2):245-252. PubMed ID: 36355605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
    Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
    Xu M; Tao Z; Wang S; Jiang Y; Qu M
    Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
    Hu K; Zhang J; Yu M; Xiong C
    Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.
    Liu S; Zha J; Lei M
    Clin Transl Oncol; 2018 Mar; 20(3):374-381. PubMed ID: 28766096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy.
    Zhang Q; Zhao J; Xu T
    Fundam Clin Pharmacol; 2023 Aug; 37(4):807-815. PubMed ID: 36691859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
    Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
    Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.